Interleukin-34 is more suitable than macrophage colony-stimulating factor for predicting liver significant fibrosis in patients with chronic hepatitis B

References

• MacLachlan JH, Cowie BC. Hepatitis B virus epidemiology. Cold Spring Harb Perspect Med. 2015;5(5):a021410–a021410. doi: 10.1101/cshperspect.a021410.
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ, Brown RS, Jr, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016;63(1):284–306. doi: 10.1002/hep.28280.
   PubMed Web of Science ®Google Scholar
• Mak LY, Wong DK, Cheung KS, et al. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. Clin Transl Gastroenterol. 2018;9:163.
   PubMed Web of Science ®Google Scholar
• Johnson KD, Laoveeravat P, Yee EU, et al. Endoscopic ultrasound guided liver biopsy: recent evidence. World J Gastrointest Endosc. 2020;12(3):83–97. doi: 10.4253/wjge.v12.i3.83.
   PubMed Web of Science ®Google Scholar
• Kim HP, Idowu MO, Mospan AR, et al. Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis. Aliment Pharmacol Ther. 2021;54(11–12):1472–1480. doi: 10.1111/apt.16674.
   PubMed Web of Science ®Google Scholar
• Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14(7):397–411. doi: 10.1038/nrgastro.2017.38.
   PubMed Web of Science ®Google Scholar
• Cheng D, Chai J, Wang H, et al. Hepatic macrophages: key players in the development and progression of liver fibrosis. Liver Int. 2021;41(10):2279–2294. doi: 10.1111/liv.14940.
   PubMed Web of Science ®Google Scholar
• Matsuda M, Seki E. Hepatic stellate cell-macrophage crosstalk in liver fibrosis and carcinogenesis. Semin Liver Dis. 2020;40(3):307–320. doi: 10.1055/s-0040-1708876.
   PubMed Web of Science ®Google Scholar
• Dultz G, Gerber L, Farnik H, et al. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus. J Viral Hepat. 2015;22(4):427–432. doi: 10.1111/jvh.12309.
   PubMed Web of Science ®Google Scholar
• Muñoz-Garcia J, Cochonneau D, Télétchéa S, et al. The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis. Theranostics. 2021;11(4):1568–1593. doi: 10.7150/thno.50683.
   PubMed Web of Science ®Google Scholar
• Preisser L, Miot C, Le Guillou-Guillemette H, et al. IL-34 and macrophage colony-stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells. Hepatology. 2014;60(6):1879–1890. doi: 10.1002/hep.27328.
   PubMed Web of Science ®Google Scholar
• Wang YQ, Cao WJ, Gao YF, et al. Serum interleukin-34 level can be an indicator of liver fibrosis in patients with chronic hepatitis B virus infection. World J Gastroenterol. 2018;24(12):1312–1320. doi: 10.3748/wjg.v24.i12.1312.
   PubMed Web of Science ®Google Scholar
• Yao H, Yang X, Yan M, et al. Correlation of serum M-CSF, CER, and TIMP-1 levels with liver fibrosis in viral hepatitis. Comput Math Methods Med. 2022;2022:6736225. 2022:doi: 10.1155/2022/6736225.
   PubMedGoogle Scholar
• Barve RA, Zack MD, Weiss D, et al. Transcriptional profiling and pathway analysis of CSF-1 and IL-34 effects on human monocyte differentiation. Cytokine. 2013;63(1):10–17. doi: 10.1016/j.cyto.2013.04.019.
   PubMed Web of Science ®Google Scholar
• Boulakirba S, Pfeifer A, Mhaidly R, et al. IL-34 and CSF-1 display an equivalent macrophage differentiation ability but a different polarization potential. Sci Rep. 2018;8(1):256. doi: 10.1038/s41598-017-18433-4.
   PubMedGoogle Scholar
• Popovic M, Yaparla A, Paquin-Proulx D, et al. Colony-stimulating factor-1- and interleukin-34-derived macrophages differ in their susceptibility to Mycobacterium marinum. J Leukoc Biol. 2019;106(6):1257–1269. doi: 10.1002/JLB.1A0919-147R.
   PubMed Web of Science ®Google Scholar
• Wang J, Xia J, Yan X, et al. Plateletcrit as a potential index for predicting liver fibrosis in chronic hepatitis B. J Viral Hepat. 2020;27(6):602–609. doi: 10.1111/jvh.13264.
   PubMed Web of Science ®Google Scholar
• Zhang YY, Hu KQ. Rethinking the pathogenesis of hepatitis B virus (HBV) infection. J Med Virol. 2015;87(12):1989–1999. doi: 10.1002/jmv.24270.
   PubMed Web of Science ®Google Scholar
• Iannacone M, Guidotti LG. Immunobiology and pathogenesis of hepatitis B virus infection. Nat Rev Immunol. 2022;22(1):19–32. doi: 10.1038/s41577-021-00549-4.
   PubMed Web of Science ®Google Scholar
• Ribeiro CRA, Beghini DG, Lemos AS, et al. Cytokines profile in patients with acute and chronic hepatitis B infection. Microbiol Immunol. 2022;66(1):31–39. doi: 10.1111/1348-0421.12947.
   PubMed Web of Science ®Google Scholar
• Li X, Liu X, Tian L, et al. Cytokine-mediated immunopathogenesis of hepatitis B virus infections. Clin Rev Allergy Immunol. 2016;50(1):41–54. doi: 10.1007/s12016-014-8465-4.
   PubMed Web of Science ®Google Scholar
• He D, Li M, Guo S, et al. Expression pattern of serum cytokines in hepatitis B virus infected patients with persistently normal alanine aminotransferase levels. J Clin Immunol. 2013;33(7):1240–1249. doi: 10.1007/s10875-013-9931-0.
   PubMed Web of Science ®Google Scholar
• Kong F, Zhou K, Zhu T, et al. Interleukin-34 mediated by hepatitis B virus X protein via CCAAT/enhancer-binding protein α contributes to the proliferation and migration of hepatoma cells. Cell Prolif. 2019;52:e12703.
   PubMed Web of Science ®Google Scholar
• Itoh Y, Okanoue T, Enjyo F, et al. Serum levels of macrophage colony stimulating factor (M-CSF) in liver disease. J Hepatol. 1994;21(4):527–535. doi: 10.1016/s0168-8278(94)80097-9.
   PubMed Web of Science ®Google Scholar
• Shoji H, Yoshio S, Mano Y, et al. Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep. 2016;6(1):28814. doi: 10.1038/srep28814.
   PubMedGoogle Scholar
• Freuchet A, Salama A, Remy S, et al. IL-34 and CSF-1, deciphering similarities and differences at steady state and in diseases. J Leukoc Biol. 2021;110(4):771–796. doi: 10.1002/JLB.3RU1120-773R.
   PubMed Web of Science ®Google Scholar
• Otsuka R, Wada H, Seino KI. IL-34, the rationale for its expression in physiological and pathological conditions. Semin Immunol. 2021;54:101517. doi: 10.1016/j.smim.2021.101517.
   PubMed Web of Science ®Google Scholar
• Charchanti A, Kanavaros P, Koniaris E, et al. Expression of syndecan-1 in chronic liver diseases: correlation with hepatic fibrosis. In Vivo. 2021;35(1):333–339. doi: 10.21873/invivo.12264.
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun X, Zhang J, et al. IL-34 regulates IL-6 and IL-8 production in human lung fibroblasts via MAPK, PI3K-Akt, JAK and NF-κB signaling pathways. Int Immunopharmacol. 2018;61:119–125. doi: 10.1016/j.intimp.2018.05.023.
   PubMed Web of Science ®Google Scholar
• Xiang DM, Sun W, Ning BF, et al. The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis. Gut. 2018;67(9):1704–1715. doi: 10.1136/gutjnl-2016-313392.
   PubMed Web of Science ®Google Scholar
• Ma Y, Bao Y, Wu L, et al. IL-8 exacerbates CCl4-induced liver fibrosis in human IL-8-expressing mice via the PI3K/Akt/HIF-1α pathway. Mol Immunol. 2022;152:111–122. doi: 10.1016/j.molimm.2022.10.011.
   PubMed Web of Science ®Google Scholar
• Kim WR, Berg T, Asselah T, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64(4):773–780. doi: 10.1016/j.jhep.2015.11.012.
   PubMed Web of Science ®Google Scholar
• Itakura J, Kurosaki M, Setoyama H, et al. Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis. J Gastroenterol. 2021;56(5):470–478. doi: 10.1007/s00535-021-01782-3.
   PubMed Web of Science ®Google Scholar